期刊
MEDICAL CLINICS OF NORTH AMERICA
卷 97, 期 1, 页码 53-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.mcna.2012.10.006
关键词
Diabetic nephropathy; Nonproteinuric; Normoalbuminuria
资金
- Keryx Biopharmaceuticals, Inc
- Chemocentryx, Inc
- Eli Lilly, Inc
- Nephrogenex, Inc
- Hypertension, and Nephrology Clinical Trials Center
- Vanderbilt University Medical Center [MCN 5-3223]
- Nashville, USA [TN 37232]
Diabetic nephropathy (DN) refers to the structural and functional changes in the kidneys of patients with diabetes mellitus (type 1 or 2). A subset of patients with presumed DN may not have overt proteinuria as a prerequisite to renal failure, contrary to the classical paradigm. No animal model fully recapitulates the human subset. All studies on this subject are observational and most lack biopsy data. Many mechanisms have been postulated, including use of renin-angiotensin system agents, recurrent bouts of acute kidney injury, genetic predisposition, and renal lesions other than DN. A well-designed biopsy study and a series of intervention trials are needed to fully understand this entity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据